Adil Abbasi, MD FACP

Learning Objectives

• Understand the neurophysiologic basis of acute pain and its relevance to clinical management.
• Learn the major etiologies and clinical presentations of acute pain in the acute care setting.
• Conduct a comprehensive assessment and diagnostic evaluation of acute pain.
• Apply a modern multimodal step-ladder approach to pharmacologic therapy.
• Select appropriate medications with safe dosing, including adjustments for liver disease, kidney disease, CHF, pulmonary comorbidities, and the elderly.
• Recognize adverse effects, contraindications, and monitoring needs for all major analgesic classes.
• Compare analgesic agents using clinically relevant variables to guide decision-making.

Background and Introduction:

Pain is among the most common reasons for emergency department visits and inpatient evaluations, with significant effects on physiologic stability, patient satisfaction, and recovery. Inadequately treated acute pain can lead to increased sympathetic activity, compromised respiratory function, impaired mobility, risk of venous thrombosis, and progression to chronic pain syndromes (Basbaum 2009; Woolf 2011). Modern acute pain management emphasizes a multimodal approach that integrates pharmacologic and non-pharmacologic strategies to optimize analgesia while minimizing opioid exposure and avoiding medication-related complications (Chou 2016).

Acute pain arises from activation of peripheral nociceptors, transmission through spinal pathways, and integration in cortical centers responsible for sensory-discriminative and affective components. Uncontrolled inflammation and repeated nociceptor activation may lead to peripheral and central sensitization, reducing pain thresholds and intensifying clinical symptoms. Understanding these physiologic processes underscores the importance of timely intervention using multiple mechanisms of action.

Pathophysiology of Acute Pain:

Acute pain begins when tissue injury triggers release of inflammatory mediators—including prostaglandins, bradykinin, serotonin, and cytokines—that sensitize nociceptors. These nociceptors transmit signals through A-delta and C fibers to the dorsal horn of the spinal cord, where neurotransmitters such as glutamate and substance P facilitate ascending conduction to the thalamus and cortex (Basbaum 2009).

Persistent nociceptive input leads to:

• Peripheral sensitization: lowered activation threshold from inflammatory mediators.
• Central sensitization: increased dorsal horn neuron excitability and reduced inhibitory modulation.

Both mechanisms contribute to hyperalgesia, allodynia, and prolonged recovery if pain is not promptly and effectively managed (Woolf 2011).

Causes of Acue Pain:

Acute pain can arise from a broad variety of etiologies, including traumatic, surgical, ischemic, infectious, inflammatory, and functional processes. Common categories include:

• Traumatic injuries: fractures, sprains, lacerations, burns.
• Postoperative pain: varying with surgical invasiveness, duration, tissue manipulation.
• Acute medical illnesses: pancreatitis, renal colic, cholecystitis, appendicitis, bowel obstruction.
• Infectious etiologies: abscess, cellulitis, meningitis.
• Ischemic causes: myocardial infarction, mesenteric ischemia, compartment syndrome.
• Exacerbation of chronic conditions: sickle cell crisis, neuropathy, arthritis.

Determining the underlying etiology is essential for targeted therapy and prevention of complications.

Clinical Assessment and Diagnostic Workup:

A thorough evaluation includes:

History: onset, character, severity, radiation, precipitating factors, prior episodes, treatments tried, comorbidities, psychosocial influences.

Assessment Tools:

• Numerical Rating Scale (0–10)
• Visual Analog Scale
• Behavioral scales in non-verbal patients

Physical Examination:
Inspection, palpation, range of motion testing, assessment of inflammation, ischemia, neurologic deficits, and referred pain patterns.

Diagnostic Workup (as indicated):

• Laboratory tests: CBC, CMP, lipase, ESR/CRP, urinalysis.
• Imaging: X-ray, CT, MRI, ultrasound.
• ECG and cardiac markers for suspected ischemic pain.
• Procedures: joint aspiration, lumbar puncture, nerve block evaluation.

Evaluation must account for high-risk features including immunosuppression, coagulopathy, advanced age, altered mental status, and multimorbidity (Baker 2020).

Medical Management: Step-Ladder Approach (Modern Multimodal Analgesia)

Current recommendations integrate a stepwise strategy similar to the WHO analgesic ladder but optimized for acute care:

Step 1: Mild Pain (Non-Opioid First-Line Therapies)

Acetaminophen

• Dose: 650–1000 mg PO every 6 hours (max 3000–4000 mg/day depending on liver status).
• Mechanism: central inhibition of prostaglandin synthesis.
• Adjustments:

• Liver disease: max 2000 mg/day in stable chronic liver disease; avoid in acute hepatitis or severe alcoholic liver disease.
• Renal disease: safe; adjust only in severe renal failure (interval prolongation).

NSAIDs (e.g., ibuprofen, naproxen, ketorolac)

• Ibuprofen: 400–600 mg PO every 6 hours.
• Naproxen: 250–500 mg PO every 12 hours.
• Ketorolac: 15–30 mg IV/IM every 6 hours (max 60 mg/day; limit to 5 days).
• Adjustments:

• CKD/AKI: avoid in CKD ≥ stage 3, AKI, or renal hypoperfusion.
• CHF: avoid due to fluid retention and increased cardiovascular risk.
• Liver disease: use cautiously; may worsen renal perfusion in cirrhosis.

Contraindications: active GI bleeding, severe renal failure, platelet dysfunction, anticoagulation, decompensated CHF.

Step 2: Moderate Pain (Add Adjuncts or Weak Opioids)

Tramadol

• Dose: 25–50 mg PO every 6 hours (max 400 mg/day; 300 mg/day if elderly).
• Adjustments:

• CKD: reduce dose; avoid extended-release formulations in CrCl < 30 mL/min.
• Seizure disorders: avoid or use extreme caution.

Adjunctive Medications

• Gabapentin: 100–300 mg PO TID (reduce dose in CKD; avoid excessive sedation in elderly).
• Pregabalin: 25–75 mg PO BID (dose-adjust in CKD).
• Muscle relaxants:

• Cyclobenzaprine: 5–10 mg PO TID (avoid in elderly; anticholinergic).
• Methocarbamol: 500–1000 mg PO TID–QID (sedation risk).

Topical Agents

• Lidocaine 5% patch: 12 hours on, 12 hours off.
• Diclofenac gel: localized musculoskeletal pain; avoid systemic NSAID effects.

Step 3: Severe Pain (Short-Acting Opioids)

Morphine

• PO: 7.5–15 mg every 4 hours.
• IV: 1–4 mg every 1–2 hours PRN.
• Avoid in: severe renal impairment (risk of metabolite accumulation → respiratory depression).

Hydromorphone

• PO: 2–4 mg every 4–6 hours.
• IV: 0.2–0.6 mg every 2–3 hours.
• Safer than morphine in renal impairment, but still requires caution.

Oxycodone

• Dose: 5–10 mg PO every 4–6 hours.
• Avoid in: severe hepatic impairment; cautious use in moderate liver disease.

Fentanyl

• IV: 25–50 mcg every 30–60 minutes or infusion.
• Preferred in hemodynamic instability; minimal histamine release.

Special Considerations

• OSA/COPD: use lowest effective dose; continuous oximetry; avoid long-acting opioids.
• Elderly: start 25–50% usual dose.
• CHF: avoid morphine in acute decompensation (histamine release causing vasodilation).

Advanced or Refractory Pain Options

Ketamine (Sub-Dissociative Dose)

• Dose: 0.1–0.3 mg/kg IV bolus; infusion 0.1–0.5 mg/kg/hr.
• Useful for trauma, opioid-tolerant patients, and patients with opioid-induced hyperalgesia.
• Minimal respiratory depression.

IV Lidocaine

• Dose: 1–1.5 mg/kg bolus; infusion 1–2 mg/kg/hr.
• Avoid in severe cardiac disease, arrhythmias.

Regional Anesthesia

• Peripheral nerve blocks, epidurals, paravertebral blocks.
• Excellent analgesia with reduced opioid needs.

Medication Use in Patients with Comorbidities

Chronic Liver Disease

• Avoid: NSAIDs, extended-release opioids, tramadol in advanced disease.
• Use with caution: oxycodone (reduced clearance), hydromorphone (preferred opioid).
• Preferred: acetaminophen ≤ 2000 mg/day, hydromorphone, fentanyl.

AKI / CKD (All Stages)

• Avoid: NSAIDs, morphine (metabolite accumulation), meperidine.
• Use carefully: tramadol (reduce dose), gabapentinoids (major dose reductions).
• Preferred: hydromorphone (low metabolites), fentanyl.

CHF

• Avoid: NSAIDs (fluid retention, worsening HF), high-dose gabapentinoids (edema).
• Preferred: acetaminophen, opioids as needed, low-dose ketamine.

OSA / COPD

• Use lowest opioid dose possible; avoid basal infusions.
• Consider ketamine or regional blocks to reduce opioid requirements.

Elderly / Frail

• Lower starting doses for all opioids and sedating agents.
• Avoid benzodiazepines, anticholinergic muscle relaxants.
• Prefer scheduled acetaminophen and topical agents.

Adverse Effects of Major Analgesic Classes

Acetaminophen

• Hepatotoxicity (dose-related)
• Minimal renal or GI effects

NSAIDs

• AKI, sodium retention, CHF exacerbation
• GI bleeding, ulceration
• Increased cardiovascular risk
• Bleeding due to platelet inhibition

Opioids

• Respiratory depression
• Sedation, delirium (especially elderly)
• Nausea, vomiting
• Constipation → requires bowel regimen
• Pruritus (morphine)
• Urinary retention
• Risk of misuse or dependence

Gabapentin

• Sedation, dizziness
• Gait instability
• Peripheral edema (worse in CHF)

Ketamine

• Dissociation, hallucinations
• Hypertension, tachycardia
• Hypersalivation

Comparative Medication Table

Summary

• Acute pain requires timely identification, pathophysiologic understanding, and structured evaluation.
• A step-ladder multimodal approach improves analgesia and minimizes opioid exposure.
• Medication selection must consider comorbidities such as liver disease, CKD, CHF, OSA, and advanced age.
• NSAIDs, acetaminophen, opioids, gabapentinoids, ketamine, and regional blocks each have defined roles.
• Safe prescribing requires awareness of dose limits, organ-based adjustments, and adverse effects.
• Comparative medication analysis allows clinicians to optimize individualized treatment plans.

Opioid Conversion Table (Equi-analgesic Doses)

All doses represent the amount roughly equivalent to 10 mg IV morphine or 30 mg oral morphine.

Methadone Conversion (Highly Nonlinear)

Methadone’s potency increases significantly with dose; never use simple linear conversion.

Only specialists should perform methadone conversions due to risks of accumulation, QT prolongation, and delayed toxicity.

Oral Morphine Milligram Equivalent (MME) Factors

These factors convert opioid dose → MME for cross-comparison.

Key Safety Notes

• Reduce calculated dose by 25–50% when switching opioids to account for incomplete cross-tolerance.
• Use greater dose reductions in elderly, frail, OSA/COPD, liver disease, or renal impairment.
• Fentanyl patch conversions apply only to opioid-tolerant patients (≥60 mg oral morphine/day for ≥1 week).
• Methadone should never be converted without expert oversight.

References (author-year)

Baker, M. 2020. Acute Pain Management in Hospitalized Adults: Safety Considerations. Journal of Hospital Medicine, 15(3): 150–158.

Basbaum, A., Bautista, D., Scherrer, G., & Julius, D. 2009. Cellular and Molecular Mechanisms of Pain. Cell, 139(2): 267–284.

Chou, R., Gordon, D., de Leon-Casasola, O. et al. 2016. Management of Postoperative Pain: Clinical Practice Guideline. Journal of Pain, 17(2): 131–157.

Dowell, D., Ragan, K., Jones, C. et al. 2022. CDC Clinical Practice Guideline for Prescribing Opioids for Pain. MMWR, 71(3): 1–95.

Woolf, C. 2011. Central Sensitization: Implications for the Diagnosis and Treatment of Pain. Pain, 152(3): S2–S15.